ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

QNCX Quince Therapeutics Inc

0.96
-0.0251 (-2.55%)
After Hours
Last Updated: 21:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Quince Therapeutics Inc NASDAQ:QNCX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0251 -2.55% 0.96 0.949 1.01 0.99 0.9202 0.95 57,847 21:30:00

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

23/11/2021 1:00pm

Business Wire


Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Quince Therapeutics Charts.

Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time.

A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain of Alzheimer’s patients and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Stacy Roughan Vice President, Corporate Communications & Investor Relations Cortexyme, Inc. ir@cortexyme.com

1 Year Quince Therapeutics Chart

1 Year Quince Therapeutics Chart

1 Month Quince Therapeutics Chart

1 Month Quince Therapeutics Chart

Your Recent History

Delayed Upgrade Clock